Comments for Med Insights

Comment on Webinar by Anonymous

Anonymous — Fri, 10 Apr 2026 07:43:31 +0000

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 15:38:26 +0000

Thank you Sir for Mentioning us 🙏

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 15:28:50 +0000

sub-therapeutic doses can still provide clinically meaningful improvements in steatosis or fibrosis, especially for patients who cannot tolerate full-dose escalation?

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 15:26:20 +0000

Please comment on the risk of optic neuritis and pancreatitis with semiglutide

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 14:40:28 +0000

Is there any role for semaglutide in compensated and decompensated CLD secondary to MASH?

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 14:39:31 +0000

What’s the dose like for MASH?

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 14:04:11 +0000

1. Do you think lower doses of Semaglutide (since in a few of your slides there were doses of 0/1, 0.2, and 0.4mg) could still offer clinically meaningful benefits in steatosis and fibrosis, particularly in populations where full-dose escalation may not be feasible?
2. Considering Asia’s unique phenotype, including higher lean MASLD prevalence and early-onset diabetes, do you expect different responses to semaglutide compared to Western populations?
3. From your experience, what are the key practical challenges in implementing the stepwise dose escalation of semaglutide in routine clinical practice globally?

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 13:55:15 +0000

Effect of Semaglutide on ckd patients

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 13:50:27 +0000

Can we use in OSA/ weight loss

Comment on Webinar by Anonymous

Anonymous — Sat, 04 Apr 2026 13:41:50 +0000